Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

McGill University

$100,000.00

Biomanufacturing stem cell-derived islets to treat diabetes in custom cell culture vessels

FY 2024-25

Summary
Canada is a worldwide leader in islet transplantation for the treatment of type 1 diabetes. The therapy consists in replacing the insulin-producing cells of the pancreas, rather than relying on insulin injections for blood glucose control. Despite the exquisite blood glucose that can be achieved, the therapy is not accessible to most people with type 1 diabetes. The main challenges are insufficient donor islet supply and the need for lifelong immune suppression after transplantation. In other projects, we are developing encapsulation devices to avoid the need for immunosuppression. In the current project, we aim to improve therapeutic cell supply by partnering with Saint-Gobain Life Sciences to mass produce stem cell-derived islets. Saint-Gobain manufactures fluoropolymer bags with high oxygen permeability which offer several advantages over other culture systems. The use of bags as bioreactor facilitates scale-up and automation. Handling of cells through closed circuits can reduce the risks of introducing bacteria or viruses into cultures. Together, we will develop bags that are tailored to challenging stem cell cultures and pancreatic differentiation. Ultimately, these tailored bags could be implemented at clinics or biomanufacturing sites in Canada to reliably produce islets and other therapeutic organoids from stem cells.
Program
Alliance Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
576853-2022
Name nom
Hoesli, Corinne CA
Department département
Chemical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2022
Award amount
100000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Biomanufacturing stem cell-derived islets to treat diabetes in custom cell culture vessels
Keywords
biomanufacturing; bioprocess engineering; cell culture bags; cellular therapy; diabetes; differentiation; fluoropolymer; materials engineering; plasma treatment; pluripotent stem cell
Application summary
Canada is a worldwide leader in islet transplantation for the treatment of type 1 diabetes. The therapy consists in replacing the insulin-producing cells of the pancreas, rather than relying on insulin injections for blood glucose control. Despite the exquisite blood glucose that can be achieved, the therapy is not accessible to most people with type 1 diabetes. The main challenges are insufficient donor islet supply and the need for lifelong immune suppression after transplantation. In other projects, we are developing encapsulation devices to avoid the need for immunosuppression. In the current project, we aim to improve therapeutic cell supply by partnering with Saint-Gobain Life Sciences to mass produce stem cell-derived islets. Saint-Gobain manufactures fluoropolymer bags with high oxygen permeability which offer several advantages over other culture systems. The use of bags as bioreactor facilitates scale-up and automation. Handling of cells through closed circuits can reduce the risks of introducing bacteria or viruses into cultures. Together, we will develop bags that are tailored to challenging stem cell cultures and pancreatic differentiation. Ultimately, these tailored bags could be implemented at clinics or biomanufacturing sites in Canada to reliably produce islets and other therapeutic organoids from stem cells.